Intra-Cellular Therapies (ITCI) Tops Q4 Loss Expectations

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.67), $0.23 better than the analyst estimate of ($0.90). Revenue for the quarter came in at $30.66 million versus the consensus estimate of $60 thousand.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• Stardust Power (SDST) Tops Q2 EPS by 1c
• Cheetah Net Supply Chain Service Inc. (CTNT) Reports Q2 EPS of $0.04